Taylor Frigon Capital Management LLC Purchases Shares of 24,618 TransMedics Group, Inc. (NASDAQ:TMDX)

Taylor Frigon Capital Management LLC bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 24,618 shares of the company’s stock, valued at approximately $1,535,000.

A number of other large investors also recently added to or reduced their stakes in TMDX. Geode Capital Management LLC grew its stake in TransMedics Group by 1.3% during the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after acquiring an additional 10,106 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its holdings in shares of TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock valued at $22,547,000 after purchasing an additional 32,605 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after purchasing an additional 6,634 shares during the last quarter. Baillie Gifford & Co. raised its stake in TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock valued at $16,824,000 after purchasing an additional 34,947 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Trading Up 1.0 %

Shares of TMDX opened at $73.76 on Thursday. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of 78.47 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a 50-day moving average of $67.29 and a 200 day moving average of $102.44.

Analyst Ratings Changes

A number of research analysts recently commented on TMDX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Piper Sandler cut their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Robert W. Baird lowered their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Finally, TD Cowen cut their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.